Accredited Investor Status Accredited Investor8221
Acquisition Warrant Personal Account Act
Activation Natural Immune System Adjustments Changes Common Stock Other Corporate Events
Administration Aggregate Exercise Price
Agreement Sell Purchase Aim
Annual Meeting Stockholders Held 2008 Approaches
Ations Audit Committee
Audit Committee Report Auditors Issued Going Concern Audit Opinion
Authority Responsibilities Authority Responsibilities Relating Board Directors Committee Membership
Authority Responsibilities Relating Evaluation Board Directors Availability Amount Reimbursement Product Candidates Manner Government Private
Available Information Base Salaries
Because Common Stock Subject Penny Rules Market Limited Because Lack Sales Marketing Experience Significant Difficulties Commercializing
Beneficial Ownership Reporting Compliance Board Committee Meetings
Board Composition Board Directors
Bridge Warrants Business Adversely Affected Animal Rights Activists
Cancer Cancer Immune System
Candidates Near-term Certain Material Weaknesses Been Identified Internal Controls
Certificate Adjustments Certificate Incorporation Bylaws Stockholder Rights Plan Delay Prevent
Certifies Changes Internal Controls Over Financial Reporting
Changes Securities Choice Law
Claims Not Available Reasonable Rate Future Clinical Pre-clinical Development Programs
Clinical Preclinical Development Programs Clinical Trials Product Candidates Expensive Time Consuming Outcome
Closing Delivery Payment Code Ethics
Cognate Cognate Therapeutics
Commitments Contingencies Committees Board Directors
Common Stock Experience Extreme Price Volume Fluctuations Lead Communication Board Directors
Compared 2005 Compared 2006
Compared 2007 Compensation Committee
Compensation Committee Interlocks Insider Participation Compensation Discussion Analysis
Compensation Goals Compensation President Chief Executive Officer
Competing Generic Medicinal Products Approved Competition
Competition Biotechnology Biopharmaceutical Industry Intense Most Competitors Substantially Competition Industry Intense Most Competitors Substantially Greater Resources
Competitors Substantially Greater Resources Complementary Other Treatments
Contingency Contractual Obligations
Controls Procedures Conversion Preferred Stock Related Matters
Cost Recovery Costs
Counterparts Covenants
Covenants Exercise Shares Creation Direct Financial Obligation
Critical Accounting Policies Estimates Current Cancer Immunotherapy Approaches
Date Report Earliest Event Reported 2007 Dcvax
Dcvax -brain Dcvax -direct
Dcvax -lb Dcvax -lung -lb
Dcvax -prostate Dcvax Characteristics
Dcvax Only Technology Clinical Development Dcvax Platform
Dcvax Process Dcvax Technology
Default Payments Default Principal
Defend Pursue Uncertain Outcome Definitions
Delay Obtaining Such Approvals Demand Registration
Determining Fair Value Sfas 123 Different Approaches
Difficult Difficulties Commercializing Research Product Candidates
Director Compensation Director Independence
Directors Nominees Director Dissenters Rights
Early Stage Development Unproven Business Strategy Limited History Ease Administration
Efficient Cost-effective Manufacturing Eligibility
Employee Executive Benefits Employee Stock Purchase Plan
Employees Employment Agreements Termination Change-in-control Arrangements
Entire Agreement Amendments Equity Compensation Plan Table
Equity Plans Equity-based Incentives
Evaluation Disclosure Controls Procedures Evaluation Disclosure Controls Procedures Internal
Event Default Exact Name Registrant Specified Charter
Executive Officers Northwest Biotherapeutics Inc Executive Stock Option Plan
Executive Stock Plan Exercise Period
Exercise Price Exercise Share8221
Exercise Warrant Expect Continue Incur Substantial Losses Never Achieve Profitability
Expenses Exposed Potential Product Liability Claims Insurance Against Not
Fail Comply Regulatory Requirements Fda
Federal Grants Federal Income Tax Considerations
Federal Regulations Fees Paid Peterson Sullivan Pllc
Financial Statements Foreign Currency Exchange Rate Risk
Form 10-k Form 8-k
Form S-8 Forward-looking Statements
Fractional Shares Further Trials Other Costly Time-consuming Assessments Product Required
General General Administrative
General Discussion Going Concern
Governing Law Governmental Regulation
Grants Plan-based Awards 2007 Hazardous Materials Comply Environmental Health Safety Laws Regulations
Held 2008 Householding
Human Immune System Impairment
Impairment Long-lived Assets Incentive Stock Options
Incidence Cancer Europe Incidence Cancer United States
Including Marketing Exclusivity Income Taxes
Incorporation Documents Bylaws Stockholder Rights Plan Delay Prevent Intellectual Property
Intellectual Property Rights Not Provide Meaningful Commercial Protection Interests Other Investors
Interpretations Investigational Products Prior Regulatory Approval Unapproved Uses
Involuntary Petition Involved Legal Proceedings Result Adverse Outcome Otherwise Harm
Lack Sales Marketing Experience Result Significant Difficulties Commercializing Legends
Level Liability Potentially Dilutive Securities Excess Authorized Number Common
License Fees Liens
Likely Continue Incur Substantial Losses Never Achieve Profitability Limitations Current Cancer Therapies
Limitations Effectiveness Controls Limited Experience Conducting Managing Clinical Trials
Liquidity Liquidity Capital Resources
Loan Agreement Lonza Patent Infringement Claim
Lost Stolen Mutilated Destroyed Warrant Low Incidence Significant Adverse Side Effects Toxicity
Lung Breast Brain Colon Melanoma Prostate Other Cancers Management Identified Significant Internal Control Deficiencies Independent Auditor
Management Loan Warrants Management Loans
Management Warrants Managements Annual Report Internal Control Over Financial Reporting
Manufacturing Manufacturing Capabilities Adversely Impact Ability Commercialize Product Candidates
Market Market Information Price Range Common Stock
Market Interest Rate Risk Marketing
Material Weakness Identified Material Weaknesses Identified
Maturity Date Medarex
Misappropriating Proprietary Rights Others Miscellaneous
Multiple Cancer Targets Multiple Therapeutic Applications
Need Raise Additional Capital Not Available Net Cashless Exercise
New Legislation Adverse Effect Business New Plan Benefits
Nomination Directors Nominations Committee
Non-employee Director Compensation Non-employee Director Stock Incentive Plan
Nonstatutory Stock Options Northwest Biotherapeutics Inc
Not Able Attract Expert Personnel Not Able Retain Existing Personnel
Not Active Liquid Trading Market Common Stock Not Obtain Maintain Orphan Drug Status Associated Benefits
Not Receive Regulatory Approvals Product Candidates Delay Obtaining Notes Payable
Notices Notices Etc
Notices Record Date Now Therefore
Operating Costs Operating Expenses
Operations Option Exercises Stock Vested
Option Provisions Organization Description Business
Otc Market Other
Other Financings Outcome Uncertain
Oversight Independent Auditors Overview
Overview Contractual Obligations Part
Part 8212 Other Information Pension Plans Deferred Compensation Severance Agreements
Perquisites Piggy-back Registration
Pipe Financing Placement Common Stock Foreign Institutional Investors
Plan Plan Remediation Material Weaknesses
Policy Audit Committee Pre-approval Permissible Non-audit Services Potential Limitation Deductions
Prevent Change Management Prevented Using Dcvax Name Europe
Price Common Stock Highly Volatile Principal Amount
Private Placement Pro Forma Information Sfas 123 Apb Opinion
Procedures Administration Process
Product Candidates Require Different Distribution Model Conventional Therapeutic Products Uncertain
Profitability Proposal Approval 2007 Plan
Proposal Approval 2007 Stock Option Plan Proposal Election Steve Harris Class Director
Proxy Solicitation Purpose
Quorum Required Recent Accounting Pronouncements
Record Date Share Ownership Reduced Business Umbrella Auto Crime Fiduciary Directors Officers
Registration Form S-3 Registration Rights
Regulation S-k Regulatory Approval Withdrawn Time
Related Party Transactions Rely Present Single Relationship Third-party Contract Manufacturer Limit
Repayment Amount Report Compensation Committee
Reporting Requirements Impose Cost Operating Challenges Required Obtain Maintain Regulatory Approval
Requirements Sarbanes-oxley Act 2002 Other Securities Laws Reporting Resale Availability Shares Issued Pipe Financing Material Adverse
Resale Availability Shares Placed Pipe Financing Material Adverse Research Development
Research Reagent Sales Restricted Securities8221
Restructuring Liabilities Results Operations
Revenue Recognition Review Approval Ratification Transactions Related Persons
Review Audited Financial Statements Review Other Financial Statements Disclosures
Revoking Proxy Rule 16b-3
Sba Sbia
Scientific Collaboration Arrangements Sec
Sec Inquiry Securities Act
Securities Exchange Act 1934 Securities Purchase Agreement
Securities Warrant Exercisable Securities8221
Series Cumulative Convertible Preferred Stock A-1 Severability
Shares Subject Plan Signatures
Soma Arbitration Sources Cash
Stock Stock Limited
Stock Option Plan Stock Option Plans
Stock Plan Stock-based Compensation
Stockholder Class Action Lawsuits Stockholder Proposals 2009 Annual Meeting Stockholders
Structure Membership Subject Sanctions Determined Promoting Investigational Products Prior Regulatory
Success Depend Partly Ability Operate Without Infringing Misappropriating Success Depend Substantially Ability Operate Without Infringing Misappropriating
Success Partially Depends Existing Future Collaborators Success Partly Depends Existing Future Collaborators
Successors Assigns Summary 2007 Plan
Summary Compensation Table Contents
Targeting Serious Cancers Effective Treatments Termination Suspension Plan
Therapeutic Antibody Therapeutic Antibody Platform
Therapeutic Antibody Product Candidates Therapeutic Products
Toucan Capital Toucan Capital Loans
Toucan Capital Loans Related Beneficial Conversions Warrant Valuations Toucan Capital Partners
Toucan Capital Partners Beneficially Own Majority Shares Common Toucan Capital Partners Beneficially Own Vast Majority Stock
Toucan Capital Partners Warrants Toucan Capital Series Cumulative Convertible Preferred Stock
Toucan Capital Series Warrant Toucan Partners
Toucan Partners Loans Toucan Partners Loans Beneficial Conversion Warrant Valuation Amortization
Toucan Partners Notes Traditional Cancer Therapy Approaches
Transfer Registration Rights Transfer Warrant
Uses Cash Value Received
Votes Required Voting Person
Voting Proxy Warrant
Warrant Shares Website Access Reports
Whereas Witness Whereof
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki